ANVS
Annovis Bio, Inc.
Key Financials
Net Income
$-28854197
↓ 17.3%
Operating Income
$-29695258
↓ 11.2%
Revenue
$0
NaN%
EPS (Diluted)
$-1.40
↑ 39.4%
Total Liabilities
$4.2M
↓ 8.4%
Shareholders' Equity
$16.9M
↑ 81.0%
Cash & Equivalents
$19.5M
↑ 85.1%
Operating Cash Flow
$-25619703.00
↓ 17.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ANVS |
| Company Name | Annovis Bio, Inc. |
| CIK | 1477845 |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 484-875-3192 |